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Abstract
Spinal muscular atrophy (SMA) is a genetic disorder caused by a deletion of the survival motor neuron 1 gene leading to
motor neuron loss, muscle atrophy, paralysis, and death. We show here that induced pluripotent stem cell (iPSC) lines
generated from two Type I SMA subjects–one produced with lentiviral constructs and the second using a virus-free
plasmid–based approach–recapitulate the disease phenotype and generate significantly fewer motor neurons at later
developmental time periods in culture compared to two separate control subject iPSC lines. During motor neuron
development, both SMA lines showed an increase in Fas ligand-mediated apoptosis and increased caspase-8 and-3
activation. Importantly, this could be mitigated by addition of either a Fas blocking antibody or a caspase-3 inhibitor.
Together, these data further validate this human stem cell model of SMA, suggesting that specific inhibitors of apoptotic
pathways may be beneficial for patients.
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Introduction
Spinal muscular atrophy (SMA) is a recessively inherited
pediatric neuromuscular disease characterized by degeneration
of spinal motor neurons, resulting in progressive muscle wasting,
paralysis, and often death [1]. Depending on the age of onset and
clinical symptoms, the disease is classified into four types (Type I–
IV). SMA is caused by a deletion or mutation in the survival motor
neuron 1 (SMN1) gene, which is responsible for the production of a
ubiquitously expressed SMN protein [2,3]. SMN protein is known
to be important in pre-messenger RNA splicing, processing and in
small nuclear ribonucleoprotein (SnRNP) biogenesis [4,5], but it
remains unclear why motor neurons (MNs) are particularly
vulnerable [6]. Humans have a second, almost identical copy of
SMN1, termed SMN2. SMN2 has a single nucleotide C to T
transition that leads to alternative splicing and removal of exon 7
rendering the majority of the protein produced unstable and non-
functional [7]. However, ,15% of SMN protein derived from
SMN2 is functional, and it has been shown that patients with more
copies of SMN2 have decreased disease severity [8]. As such, drug
development strategies have targeted SMN2 for therapeutic
intervention [9–12].
The neuronal apoptosis inhibitor protein (NAIP), found on
chromosome 5 in close proximity to SMN1, is mutated in greater
than half of all SMA type 1 cases [13] and loss of SMN1 itself may
also lead to motor neuron cell death through apoptosis [14,15].
While it has been shown that SMN on its own has minimal anti-
apoptotic effects, a significant reduction in both Fas-mediated and
Bax-mediated apoptosis was observed through direct interaction
with the anti-apoptotic factor Bcl-2 [16]. However, the interaction
of Bcl-2 and SMN is contentious, as another study clearly showed
that SMN and Bcl-2 do not directly interact in vivo and suggested
that overexpression of these proteins in vitro may have resulted in
aggregation artifacts in the Iwahashi et al. study [17]. Although the
exon 7 deleted form of SMN extends the life of ‘‘severe’’ SMA
mice [18], it has been shown not to have a direct anti-apoptotic
benefit, thus providing a possible explanation as to why SMN2
does not prevent the apoptotic process [16,19]. Furthermore,
other reports have demonstrated an increase in apoptosis and
aberrant motor neuron growth in the absence of SMN in SMA
animal models and in vitro [20–23]. Importantly, motor neuron
protection was conferred after anti-apoptotic intervention in these
models.
Although there are several transgenic mouse models of SMA
available [24–26], the fundamental biological differences between
mice and humans will always be a barrier to translating these
studies to human clinical trials. Thus the generation of iPSCs from
adult human fibroblasts [27–29] is opening up a complementary
field of human disease modeling for neurological diseases [30]. We
have previously shown that iPSCs derived from a Type I SMA
patient showed a selective loss of MNs over time in culture [31].
Therefore, in the current study, we sought to investigate the
pivotal cell death signaling mechanisms leading to fewer MNs,
using the original patient line and a newly generated virus-free line
from a second Type I SMA patient. We demonstrate that both
SMA patient-iPSC lines reproducibly have diminished MN
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phenotype observed in SMA MN cultures involves the activation
of Fas ligand-mediated apoptotic pathway via caspases-8 and -3.
Finally, blocking this pathway prevents MN cell death suggesting
that this pharmacological approach may be important for patients
with this disease.
Results
Generation of a Virus-free iPSC Line from a Second SMA
Patient
With a large number of patient lines and subsequent clones
being generated by a number of consortia and other groups, the
iPSC lines reported here will follow the naming convention
recently suggested [32]. In our initial report, we generated iPSCs
from fibroblasts of a type 1 spinal muscular atrophy (SMA1)
patient (Coriell repository identifier: GM03813; iPSC line
UW13iSMA-i.6, referred here as 13iSMA) and his unaffected
mother (GM03814; iPSC line UW14iCTR-i.2, referred here as
14iCTR) [31]. In order to reproduce the phenotype seen in an
independent line, we generated a second iPSC line from another
SMA1 patient (23 month old) fibroblast sample (GM09677; iPSC
line UW77iSMA-e.x, referred here as 77iSMA) by a single
nucleofection with episomally expressed oriP/EBNA1-based
pluripotency plasmids in combination with small molecules [33].
Seven clones were generated (Fig. 1, Fig. S1A) and have been
validated for pluripotency markers including expression of cell
surface (SSEA4, TRA-1-60 and TRA-1-81) and nuclear (Oct4,
Nanog and Sox2) proteins (Fig. 1A, Fig. S1B). Using qRT-PCR
analyses, we failed to detect any residual transgene expression in
the 77iSMA iPSC clones as no significant differences were
observed between total and endogenous gene expression (Fig. 1B,
Fig. S1C). The absence of SMN1 and the maintenance of SMN2
expression in the SMA-iPSCs were also confirmed using PCR
(Fig. 1C). Clone 77iSMA.e12 produced a teratoma after 6 weeks
in SCID mice (Fig. 1D) and was therefore selected for further
examination and subsequently referred to as 77iSMA. We also
included a separate control iPSC line (GM02183; iPSC line
UW83iCTR-i.8, referred here as 83iCTR [34]) for analysis in this
study, which was characterized using the standard battery of
pluripotency assays (Fig. S2A–C).
Motor Neurons can be Produced from Control and SMA
Patient iPSCs
We developed a simple method to generate multipotent neural
stem cells (NSCs) from human iPSCs without utilizing embryoid
body formation (Fig. 2A). The iPSC colonies were lifted from
mouse embryonic fibroblast feeder layers and cultured in
suspension medium containing high concentrations of EGF
(100 ng/ml) and bFGF (100 ng/ml) supplemented with heparin.
Spherical aggregates of NSCs form within 1 week from both the
SMA patient and unaffected control iPSC colonies and could be
expanded for over 40 weeks in culture, termed NSCs
EFH. These
NSCs could be driven towards motor neuron (MN) fate by first
caudalizing with all-trans retinoic acid (ATRA) and then
ventralizing with purmorphamine (PMN; Smoothened agonist in
the Hedgehog signaling pathway; [35]). Emerging MNs were
characterized by immunocytochemistry for early MN markers,
Olig2, HB9, Islet-1, Nkx2.2, Nkx6.1, and Lhx3 (Fig. 2B), and later
expression of intermediate/mature MN markers, Lhx1, SMI-32 (a
200 kDa neurofilament protein) and choline acetyltransferase
(ChAT) (Fig. 2C,D). Further, co-expression of HB9/ChAT
confirmed regional specification (Fig. 2D). Finally, we were able
to identify nuclear gems and cytoplasmic SMN in ChAT positive
neurons differentiated from control 83iCTR cell line (Fig. 2D),
whereas SMA-iPSCs maintained their characteristic loss of SMN
protein over time in differentiation (Fig. S3). All four iPSC lines
were capable of generating significant numbers of MNs at 3 weeks
of differentiation (Fig. 3B).
SMA Patient-derived Motor Neurons Degenerate Over
Time
We previously reported that following robust MN production at
4 weeks, there was then a significant decline in MNs over time in
the SMA cultures [31]. In agreement with this previous study, we
again observed significantly fewer MNs over time following ten
weeks of differentiation for both the 13iSMA (2.6%) and 77iSMA
(7.2%) cultures when compared to controls 14iCTR (11.9%) and
83iCTR (17.1%) (Fig. 3A). Interestingly, while the total number of
neurons was similar between the lines, the new 77iSMA line
actually had significantly more MNs at early time points (Fig. 3B),
probably reflecting inter-line variability. However, the longitudinal
analyses revealed that while all cultures continued to undergo
neurogenesis at similar levels over time, and the control cultures
continued to produce motor neurons between 3–10 weeks, the
SMA cultures were found to contain significantly fewer MNs
(p,0.01; Fig. 3B). In addition to a decline in MN numbers and/or
lack of production, there was also a significant reduction in the
total cell body area over time (0.82–0.94 fold change, p,0.05) and
number of processes (0.85–0.92 fold change, p,0.05) of SMI-32+
cells in both SMA lines when compared to the control line, which
increased 1.3 fold (Fig. 3C). This single representative experiment
allowed a direct comparison between the different iPSC lines
plated at the same time, density and identical passage numbers.
We next tested the robustness of the model across multiple
experiments and different iPSC lines. Clearly there is some inter-
line and inter-experiment variability chiefly due to deviations in
exact plating cell densities as a result of clustering of motor neuron
precursor aggregates, which subsequently affects the stress levels
within the culture system. However, a meta-analysis of four
independent MN differentiation experiments revealed that there
were significantly fewer SMI-32+ cells at late differentiation time
points (8–10 weeks) in the two SMA cell lines (13iSMA and
77iSMA) compared to two control cell lines (14iCTR and
83iCTR), while the TuJ1 numbers constantly increased between
1.5–2 fold over this same time period (Fig. 3D). Taken together,
these data confirmed that this model was reliable and reproduc-
ible, and agreed with our previously published work [31].
Apoptotic Markers are Activated in SMA Motor Neuron
Cultures
We next wanted to establish whether SMA MNs were dying
over time in culture, which has previously also been shown to
occur in SMA mouse models [20,21]. MN cultures derived from
SMA and control lines were first fixed and stained with Hoechst
33528 to detect nuclear condensation, a hallmark of apoptosis
[36]. The percentage of apoptotic cells at 7–10 weeks of
differentiation was significantly greater in the 13iSMA (12.6%)
and 77iSMA (13.1%) iPSC motor neuron cultures compared to
the control iPSCs MN cultures, 14iCTR (7.7%) and 83iCTR
(8.2%) (Fig. S4), suggesting that SMA-iPSC MN cultures are
undergoing active apoptosis.
Apoptosis is known to be executed by the cleavage of pro-
caspases, such as initiators (caspase-8 and caspase-9) and
executioners (caspase-3 and caspase-7), to their active cleaved
forms. We first examined whether the final executioner caspase-3
was involved in SMA specific MN cell death using an antibody
Apoptosis in SMA-iPSC Motor Neurons
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condensation assay, a representative experiment exhibits signifi-
cantly more active caspase-3 positive cells at 8 weeks of
differentiation in the 13iSMA (13.2%) and 77iSMA (13.6%) iPSC
cultures compared to the 14iCTR (6.8%) and 83iCTR (7.1%)
cultures (Fig. 4A,B). A further meta-analysis over four independent
MN differentiation experiments also showed a significant increase
in cleaved caspase-3 positive cells at late differentiation time points
(8–10 weeks) in the two SMA cell lines when compared to controls
(Fig. 4C). Immunoblot analysis confirmed this result revealing
higher levels of cleaved caspase-3 isoforms (17/19 kDa) in the
13iSMA-iPSC MN cultures (Fig. 4D,E). This result was further
substantiated by a significant increase in the ratio of cleaved
caspase-3 to procaspase-3 in 8 week old 77iSMA MN cultures
using a human apoptosis proteome profiler array (Fig. 4E). We
next asked whether apoptosis was occurring in the developing
MNs by double labeling with antibodies to cleaved caspase-3 and
SMI-32. Significantly more double positive MNs were observed in
the SMA cell lines (6.9% for 13iSMA (p,0.05) and 10.9% for
77iSMA (p,0.01)) compared to the control lines (2.3% for
14iCTR and 3.3% for 83iCTR) (Fig. 4F,G). Very similar results
were seen with double labeling of cleaved caspase-3 with ChAT
(Fig. 4G). Taken together, these data show that there is enhanced
apoptosis in the SMA lines.
SMA Motor Neuron Cultures Show Increased Caspase-8
Activation and Levels of Fas Ligand
We next explored which apoptotic pathways led to the
expression of cleaved caspase-3 in SMA. We did not observe
changes in the levels of mitochondrial-associated apoptosis
signaling molecules including Bcl-2, Bax, cleaved caspase-9, and
AIF (Fig. 5A and data not shown). However, using western blot
analysis we identified an increase in activation of initiator
procaspase-8 to its cleaved form in the SMA-iPSC MN cultures
compared to control (Fig. 5A). This was also confirmed by
immunocytochemistry (Fig. 5B) and luminescence activity (Fig. 5C)
in 13iSMA MN cultures. Greater numbers of HB9/cleaved
Figure 1. Generation and characterization of a new SMA-iPSC line. (A) Bright field images of the 77iSMA-e.12 SMA line showing typical
pluripotent stem cell colony morphology, made by a combination of episomal vectors. Immunostaining shows expression of embryonic stem cell
surface antigen SSEA4, Tra-1-60, Tra-1-81, and nuclear Oct4. (B) Quantitative RT–PCR analyses of OCT4, SOX2, NANOG, cMYC, KLF4, LIN28 expression in
seven clones of 77iSMA iPSCs relative to H1 hESCs. ‘‘Endogenous’’ indicates that primers were included in the 39 untranslated region (UTR) measure
expression of the endogenous gene only, whereas ‘‘total’’ indicates that primers in coding regions measure expression of both the endogenous gene
and the transgene if present. Gene expression differences were not significant (ns) by one-way ANOVA and data are represented as mean 6 SD. (C)
77iSMA and 13iSMA iPSCs show the expected lack of SMN1 expression and maintenance of SMN2 expression. (D) Hematoxylin and eosin (HE)
histology from teratoma tissue in nude mice kidney capsule grown for 6 weeks, showing striated muscle (mu) and a vessel (ve) of mesodermal origin,
endodermal-epithelia (en-ep) of intestinal character, and ectodermal epithelia of peridermal (p-ep) character. Scale bars: 100 mm.
doi:10.1371/journal.pone.0039113.g001
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compared to the 14iCTR MNs (Fig. 5B). Caspase-8 is an
important player in the apoptotic pathway that is triggered by
the binding of ligands (e.g. Fas ligand (FasL), a TNF family
transmembrane protein) to their receptors leading to the
recruitment of adaptor proteins [37]. As such, we observed
increased levels of membrane-bound Fas ligand (mFasL) by
immunocytochemistry (Fig. 6A) and immunoblotting (Fig. 6B) in
the SMA patient MN cultures at 6 weeks of differentiation.
Collectively, these results show that apoptotic cell death in the
SMA MN cultures is mediated through FasL, caspases-8 and -3
signaling.
Motor Neurons are Rescued by Blocking Apoptosis in
SMA MN Cultures
In order to establish whether inhibiting apoptotic pathways
could rescue the diminished MN numbers in the SMA lines, we
first utilized the antagonistic ZB4 clone of anti-Fas monoclonal
antibody (FasNT Ab), previously shown to block the apoptosis-
inducing activity mediated through the Fas receptor pathway [38].
Treatment with FasNT Ab beginning at week 2 and maintained
for the duration of the differentiation process significantly
increased MN number in SMA-iPSC cultures at 8 weeks of
differentiation (33% for 13iSMA and 31% for 77iSMA, p,0.05
(Fig. 7A). Similarly, culturing 13iSMA MNs in the presence of the
caspase-3 specific inhibitor Z-DVED-FMK starting at week 3
significantly rescued the SMI-32+ cell population to the level of
the 14iCTR (Fig. 7B). Collectively, these data show that the
diminished MN numbers in SMA patient-iPSC lines is dependent
upon apoptosis, specifically through the Fas-mediated pathway.
Discussion
The molecular mechanisms that lead to the development of the
SMA pathology are unclear. For this reason, despite substantial
research in the area, an effective treatment for this disease does not
yet exist. As such, there is a need to identify therapeutic strategies
that delay the advance of SMA pathology. Following lineage
restriction of hiPSCs to generate motor neurons, previously shown
to be functional [31] and electrophysiologically active [39], we
identified molecular markers of apoptosis in SMA-iPSC MN
cultures. In the present study, we demonstrate using two
independent SMA and two control iPSC lines that there were
significantly fewer MNs at 10 weeks of differentiation from SMA
patient-iPSCs. Importantly, we show here that this phenotype
could be rescued by blocking the Fas receptor or inhibiting
caspase-3. As such, our data suggest that apoptosis plays an
important role in disease progression, and therapies targeting this
cascade may have important clinical applications.
The lentiviral SMA type 1 line (13iSMA) [31] used in this study
produces similar number of SMI-32+ MNs compared to two
control lines at early time points in culture, while the new virus-
free SMA type I line (77iSMA) initially produces far greater MNs
than all the lines combined. This would suggest that in this SMA
stem cell model, the patient iPSC lines are competent in
generating MN progenitors at early stages of differentiation and
Figure 2. Motor neuron (MN) differentiation from iPSCs. (A) Schematic representation of MN differentiation from iPSCs out to 10 weeks. (B, C
and D) Differentiated human iPSCs are capable of developing into both (B) early, (C) intermediate, and (D) mature MN markers indicative of lineage
restriction. (D) Detection of SMN protein in the nuclei (gems) and cytoplasm of choline acetyltransferase (ChAT) positive MNs derived from control
iPSCs (83iCTR). Representative images for MN differentiation depicted here are from healthy control subject iPSCs (14iCTR or 83 iCTR). Scale bars:
50 mm.
doi:10.1371/journal.pone.0039113.g002
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suggested in a recent study examining post-mortem pathological
analyses from spinal cords of SMA patients [40]. Between 3 and
10 weeks of differentiation, the SMA cultures show a decline in the
total number of MNs in comparison to the control cultures
(Fig. 3B). This could either represent death of the motor neurons
over time, or failure to increase in number due to deficits in motor
neuron progenitor pools. However, we show here that greater
numbers of MNs in the SMA cultures were double labeled with
caspase-3 (Fig. 4F,G) when compared to control cultures,
suggesting that at least a proportion of MNs were actively
undergoing apoptosis.
We have observed that there is inter-line variation in the
propensity of hiPSCs and hESCs towards terminal MN differen-
tiation, which is likely due to the intrinsic characteristics of the
lines. This observation is confirmed by a recently published study
where 16 iPSC lines were tested by independent labs for MN
production using standard protocols [41]. Although all cell lines
were capable of generating MNs, significant and reproducible
quantitative differences were revealed in the propensity of the lines
for terminal differentiation. This cautions against the direct
comparison of cell numbers at any stage – pluripotent stem cells,
progenitors or terminally differentiated derivatives – between
control and patient iPSC lines for a reproducible disease
phenotype. Therefore, in cases where a disease phenotype is
expected in differentiated cells, we suggest that validation of a
disease phenotype should be performed by a temporal, longitu-
dinal study collecting data at multiple time points for an intra- and
inter-line comparison. Using this methodology, each cell line
serves as its own control with regard to starting and ending
numbers of specific types of neurons or other cell types. Here we
show that MNs generated from SMA patients undergo selective
degeneration in a temporal manner, and that this is associated
with the activation of the Fas-mediated apoptosis. Our findings of
MN degeneration in SMA-iPSC lines are also confirmed by a very
recent report which shows that five clonal iPSC lines from a single
SMA patient (GM09677 patient fibroblasts were used in this
report analogous to the source of the 77iSMA line used in our
study), made using retroviral integrating vectors, exhibit a reduced
capacity to form MNs and abnormalities in neurite outgrowth
[42], all of which could be rescued by ectopic expression of SMN.
The discovery that the neuronal apoptosis inhibitor protein
(NAIP) on chromosome 5 was mutated in greater than half of all
SMA type 1 cases [13] led to early suggestions that apoptosis may
be directly involved with SMA. Interestingly, deletions in the
NAIP gene in the same patients may increase the severity of
disease and thus act as a modifier [14,15]. Furthermore, while the
major function of SMN is the biogenesis of spliceosomal snRNPs,
it has also been shown to modulate apoptosis [16]. Further support
for involvement of apoptosis in SMA comes from a number of in
vitro and in vivo studies [16,19–23,43]. Our data showing significant
increases in active caspase-3 within the differentiating SMA MN
Figure 3. SMA MN cultures display a degenerative phenotype. (A) At 10 weeks of differentiation, both SMA patient-iPSC lines show a
significant reduction of SMI-32+ MNs compared to both control iPSC lines. However, the Tuj1+ (bIII-tubulin) neuronal population is unaffected. These
data are represented as mean 6 SEM and are quantified in (B and C); the graphs are represented as percent positive TuJ1 or SMI-32 cells of the total
Hoechst positive population. There was no significant difference in Tuj1 positive neuron numbers observed between the control and SMA cells at 3, 7
and 10 weeks of MN patterning. (C) There is a reduction of total cell body area and total number of processes in the SMA cell lines at late stages of
differentiation compared to control iPSCs. (D) Meta-analysis of SMI-32 and TuJ1 counts confirms a significant reduction in SMI-32+ MNs in SMA cells.
(C and D) Data are represented according to the longitudinal differentiation equation (Materials and Methods) as mean 6 SEM, n=4 independent
experiments. Scale bars =50 mm. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0039113.g003
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human disease. This is in contrast to a recent report from Ito and
colleagues in which no significant difference in caspase-3
activation was observed between SMA and control fetal post-
mortem spinal cord tissue samples [40]. This could be due to a
variety of reasons including timing of analysis, tissue processing,
methods of detection, and intrinsic differences between in vitro and
in vivo studies. Nevertheless, apoptotic signals are activated in our in
vitro model and warrant further investigation in SMA pathophys-
iology.
Clearly apoptosis is a complex process where one of the major
pathways involves binding of ligands, such as TNF or FasL, to
their death receptors (TNFR or FasR, respectively), leading to the
recruitment of adaptor proteins and the subsequent activation of
caspase-8 [44]. Downstream activation of caspase-3 leads to
cleavage of substrates vital to cell function. Here we show that cells
within MN cultures of SMA patient-iPSCs showed significant
chromatin condensation as well as activation of initiator caspase-8
and executioner caspase-3. While we cannot eliminate some
involvement of mitochondrial-dependent pathways as previously
Figure 4. Detection of apoptosis in SMA MN cultures. (A and B) Both SMA-iPSC MN cultures showed an increase in cleaved caspase-3 staining
over time compared to control iPSC MN cultures. Representative images are shown in B.( C) Meta-analysis confirms the increase in caspase-3
activation in SMA-iPSC MN cultures. Data are represented according to the longitudinal differentiation equation (Materials and Methods) as mean 6
SEM, * p,0.05, n=4 independent experiments. (D and E) Western blot analysis of cell lysates from SMA-iPSC MN cultures shows significant and
sustained activation of caspase-3 compared to control iPSCs. (F and G) There were significantly more cleaved caspase-3/SMI-32 (F) and cleaved
caspase-3/ChAT (G) double positive cells in both SMA-iPSC lines compared to control iPSC lines over time. Data in (F) are represented as mean 6
SEM. White arrows indicate doubled labeled SMI-32 MNs also positive for cleaved caspase-3 and the 13iSMA and 77iSMA cultures Scale bars: 50 mm
(B) and 25 mm( G).
doi:10.1371/journal.pone.0039113.g004
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appears to be death receptor-mediated. Membrane-bound FasL is
a potent activator of the death-receptor mediated apoptosis, and
we showed increases in membrane-bound FasL in the SMA
samples corresponding to the time of significant MN loss (Fig. 6).
Blocking this pathway during differentiation with Fas neutralizing
antibody rescues the MNs, further supporting a role for this
pathway being active in this disease. SMN levels do not vary
temporally in this culture system over the course of MN
differentiation in SMA-iPSC lines (Fig. S3), but the current data
do not identify a mechanism linking diminished SMN protein to
up-regulated Fas ligand. Therefore, further studies will address
FasL processing, splicing, transport, and translation specifically in
relation to reduced SMN.
During development, apoptosis plays a critical role in neuron
pruning such that 50% of MNs initially generated in the spinal
cord die [46]. Target tissues play an important role in providing
necessary trophic support to maintain MNs. However, embryonic
MNs have been shown to activate apoptosis through binding of
FasL and activation of caspase-3 independent of trophic factor
support [47]. Caspase-3 activation has been observed in healthy
control and SMA patient fetal post-mortem spinal cord tissue [40].
Similarly, we also observe caspase-3 activation in the MN cultures
from the control and SMA lines at early time points (Fig. 4D),
which is presumably due to active apoptotic signals upon the
transition from a pluripotent stem cell state to a differentiated
state, reflecting non-MN and MN death. If MNs are naturally
primed to undergo apoptosis during development, perhaps the
lack of SMN in SMA-iPSCs maintains a hyperactive apoptotic
process via prolonged caspase-3 activation, and may also explain
the disease phenotype observed in patients and experimental
models. Alternatively, the MNs in our culture system may be
lacking the appropriate target tissue or trophic support. Notably,
blocking caspase-3 activation with a commercial inhibitor rescues
the MN degeneration phenotype in SMA, signifying the impor-
tance of this pathway in our disease model.
The iPSC-derived cultures in this study contain a mixed
population of cell types, including ChAT positive motor neurons,
Tuj1 positive neurons, and GFAP positive astrocytes (Fig. S5). At
this time, technical complexities, such as purification and survival
of mature MNs from iPSCs by sorting or panning, make it difficult
to distinguish whether a cell autonomous or a non-cell autono-
mous apoptotic process is involved. The non-neuronal cells play a
determinant function in the vulnerability of the neurons in several
pathological conditions [48]. Astrocytes, for example, have been
shown to dramatically alter the health and survival of MNs in
transgenic models of ALS [49] and FasL is known to promote
astrocyte reactivity and production of proinflammatory cytokines
[50,51]. Since SMN1 is absent in all cell types, the possibility
remains that astrocytes may themselves be dysfunctional and
contributing to the apoptotic process. Future studies targeting the
HB9 motor neuron-specific promoter in iPSCs in conjunction with
co-culture assays will address this issue. The protective effect of
FasL antagonistic antibody may occur though an indirect
mechanism implicating surrounding cells in our MN cultures.
During the past several years, our understanding of the
mechanisms mediating cell death in neurologic diseases has
improved considerably. The fact that activation of these pathways
is a feature of a broad range of neurologic diseases makes them
important and attractive therapeutic targets. Therefore, conferring
neuroprotection by interrupting apoptosis and preserving mito-
chondrial integrity are being actively explored by companies and
academics. For example, monoamine oxidase inhibitors, selegiline
and rasagiline, in Alzheimer’s and Parkinson’s disease [52], and
dexpramipexole, a lower affinity non-ergot dopaminergic auto-
receptor agonist, for the potential treatment of amyotrophic lateral
sclerosis [53] are being investigated. Additionally, combination
therapies targeting apoptosis with other pathways are being tested
for Parkinson’s and Alzheimer’s disease including antioxidants, cell
cycle inhibitors, JNK inhibitors, GSK3b inhibitors, and STATINS
[54], which could also be suitable strategy for delaying the
progression of in SMA. Despite the lack of information from
Figure 5. Activation of caspase-8 in SMA MN cultures. (A) Western blot analysis of MN patterned SMA-iPSCs cell lysates at 8 weeks show
reduced SMN and MN markers Islet-1 and HB9, but increased activation of caspase-8 compared to control iPSCs. There was no difference in
expression levels of Bax, Bcl-2, and AIF. GAPDH was used as a loading control. (B) Immunocytochemistry detected an increase in cleaved caspase-8 in
13iSMA MN cultures. White arrows indicate doubled labeled HB9 positive MNs that are also positive for cleaved caspase-8. (C) An increase in caspase-
8 activation in 13iSMA MNs was confirmed with the Caspase Glo-8 assay, measuring caspase-8 activity by release of luminescence upon activation of
caspase-8 and a cleavage of a target peptide. Data are represented as mean 6 SEM, n=3 experiments.
doi:10.1371/journal.pone.0039113.g005
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39113Figure 6. Fas ligand over-expression in SMA MN cultures. (A and B) Expression of total membrane-bound Fas ligand was increased in 13iSMA
cells after 6 week differentiation seen by (A) immunocytochemistry and (B) Western blot analysis. Data shown here are representative of n=3
independent experiments.
doi:10.1371/journal.pone.0039113.g006
Figure 7. Rescuing motor neuron loss in SMA cell lines. (A) Treatment with Fas neutralizing antibody (FasNT Ab) significantly protected
77iSMA and 13iSMA SMI-32+ motor neurons at 8 weeks relative to 4 weeks. Data are expressed according to the longitudinal differentiation equation
(Materials and Methods) as mean 6 SEM, * p,0.05, n=2 independent experiments. (B) Treatment of 13iSMA MN cultures with the specific caspase-3
inhibitor Z-DVED-FMK significantly protected SMI-32+ MNs at 8 weeks of differentiation, * p,0.05, n=2 independent experiments.
doi:10.1371/journal.pone.0039113.g007
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39113clinical trials, natural product compounds such as resveratrol and
melatonin are attracting considerable attention because of their
antioxidant and anti-apoptotic action in addition to low toxicity in
humans [55,56]. Resveratrol has also been shown to increase full
length SMN transcript and protein in SMA fibroblasts [57]. The
data presented here further suggest that apoptotic pathway
inhibition may be a therapeutically relevant target for SMA.
Furthermore, by scaling up the current system for high content
screening studies [58], it may be possible to test these novel
compounds for efficacy in this novel human model prior to
administration to patients, and thus increase the possible chances
of success.
Materials and Methods
Ethics Statement
Human fibroblast cell lines were obtained from the Coriell
Institute for Medical Research. The Coriell Cell Repository
maintains the consent and privacy of the donor fibroblast samples.
All the cell lines and protocols in the present study were carried
out in accordance with the guidelines approved by institutional
review boards at the University of Wisconsin-Madison, Cedars-
Sinai Medical Center, and Medical College of Wisconsin. All the
animal care treatment protocols and procedures in the present
study were carried out in accordance with the guidelines approved
by the Cedars-Sinai Institutional Animal Care and Use Commit-
tee (IACUC) and National Institutes of Health standards of animal
care.
Virus-Free Cellular Reprogramming
Fibroblast cell lines from patients with SMA (13iSMA:
GM03813; 77iSMA: GM09677) and normal controls (14iCTR:
GM03814; 83iCTR: GM02183) were obtained from the Coriell
Institute for Medical Research. Reprogramming of the new
77iSMA line was performed using pEP4-E02S-CK2M-EN2L and
pEP4-E02S-ET2K vectors (Addgene, according to previously
published protocols [28]). Detailed descriptions of these proce-
dures are provided in Text S1.
Neural Stem Cell Culture and Motor Neuron
Differentiation
Briefly, iPSC colonies were differentiated to make NSCs by
gently lifting from MEF feeders in ultra-low attachment flasks with
Stemline Neural Expansion Media (Sigma) supplemented with,
EGF (100 g/ml), fibroblast growth factor-2 (FGF-2; 100 ng/ml),
and heparin (5 mg/ml). NSC spheres stabilized 3 weeks after the
first passage following generation and were utilized regularly for
further motor neuron (MN) differentiation by placing NSC spheres
were placed in neural induction medium (1:1 DMEM/F12 and
1% N2) in the presence of all-trans retinoic acid (RA; 0.1 mM) for
1 week. This was followed by the addition of purmorphamine
(PMN; 1 mM) or Sonic Hedgehog (SHh; 10 ng/ml) for another 1–
3 weeks and plate down on poly-ornithine/laminin-coated
coverslips to induce maturation to MNs. RNA was isolated and
used for gene expression analysis using primers listed in Table S1.
For immunostaining and immunoblotting, undifferentiated or
differentiated iPSCs were fixed with 4% paraformaldehyde and
stained using the antibodies listed in Table S2. Detailed
descriptions of these procedures are provided in Text S1.
Apoptosis Profiler Array
Expression profiles of apoptosis-related proteins (pro- and
cleaved-caspase-3) spotted in duplicate on nitrocellulose mem-
branes along with capture antibodies were analyzed using Human
Apoptosis Proteome Profiler Array (R & D systems), according to
manufacturer’s instructions. Briefly, equal amounts (200 mg) of
protein from 8 week differentiated motor neuron cultures lysate
were incubated overnight with the membranes, followed by
washes at each intermediate step, incubation with detection
antibodies, Streptavidin-HRP and chemiluminescent reagents
(Pierce) and exposure to X-ray film.
Apoptosis Inhibitor Treatment
SMA and control iPSCs were treated with either Fas
neutralizing antibody (FasNT, clone ZB4, 300 ng/ml) or cas-
pase-3 inhibitor (Z-DVED-FMK, 10 mM, R&D Systems) begin-
ning at 2–3 weeks of MN differentiation through fixation at 8
weeks of differentiation. Fresh inhibitor was added two times a
week with each medium change.
Longitudinal Differentiation Calculations
In order to avoid issues associated with inherent inter-line
variations in the propensity of hiPSCs and hESCs to proceed
towards terminal neuronal differentiation, we devised a method to
perform intra- and inter-line comparison by collecting data at
multiple time points for a temporal and longitudinal study. Cell
counts were performed and measurements collected at 3, 4, 7, 8,
and 10 weeks of differentiation and were put into the following
longitudinal differentiation cell ratio formula:
Ratio~ 7 to 10 wk: ðÞ avg:7 3 to 4 wk: ðÞ avg: ½ 
Measurements made at 3 and 4 weeks (i.e. early) or 7 to 10
weeks (i.e. late) were averaged and represented as ‘‘(3 to 4 wk.)avg.’’
and ‘‘(7 to 10 wk.)avg.’’, respectively. In this case each cell line serves
as its own control with respect to starting and ending numbers for
motor neurons produced.
Statistical Analysis
Prizm software (GraphPad software, La Jolla, CA) was used for
all statistical analyses. All counting data from immunocyto/
histochemical analyses and cell survival were expressed as mean
values 6 SEM and analyzed by two-tailed t-test or two-way
ANOVA with Bonferonni post hoc test. Differences were considered
significant when p,0.05.
Supporting Information
Figure S1 Characterization of a new virus-free SMA
iPSC line. (A) Bright field images of three different clones from
77iSMA show typical pluripotent stem cell colony morphology on
irradiated mouse embryonic fibroblasts (MEFs). These lines were
made by a combination of two episomal vectors, pEP4-E02S-
CK2M-EN2L and pEP4-E02S-ET2K. (B) Immunostaining of
three clones from 77iSMA iPSCs shows expression of embryonic
stem cell surface antigen SSEA3 and nuclear Oct4. (C)
Quantitative RT–PCR analyses of OCT4, SOX2, NANOG, and
LIN28 expression in seven clones of 77iSMA iPSCs relative to H1
ESC. ‘‘Endogenous’’ indicates that primers were included in the 39
untranslated region measure expression of the endogenous gene
only, whereas ‘‘total’’ indicates that primers in coding regions
measure expression of both the endogenous gene and the
transgene if present (Table S1).
(TIF)
Figure S2 Characterization of a new control iPSC line.
(A) Bright field image of one clone different clones from 83iCTR
Apoptosis in SMA-iPSC Motor Neurons
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39113show typical pluripotent stem cell colony morphology on
irradiated mouse embryonic fibroblasts (MEFs). This line was
generated by a combination of lentiviral constructs expressing
OCT4, SOX2, c-MYC, KLF-4, NANOG, and LIN28. Immunocyto-
chemical staining of embryonic stem cell surface antigens SSEA-4,
TRA-1-60 and nuclear Oct4. Scale bars: 50 mm. (B) G-band
karyotyping showing a normal karyotype of this line. (C)
Quantitative RT–PCR analyses of OCT4, SOX2, NANOG, c-
MYC, KLF4, LIN28 total and endogenous gene expression in
83iCTR-i.8 clone of relative to H1 hESC (Table S1).
(TIF)
Figure S3 Loss of SMN protein is maintained during
differentiation in SMA iPSC motor neuron cultures. MN
cultures from the SMA lines maintain consistent loss of SMN
protein during differentiation. Representative Western blots from
cell lysates of 13iSMA line harvested at 1, 4 and 8 weeks of
differentiation are shown here. Cyclooxygenase IV (COX IV) is
used as a housekeeping loading control.
(TIF)
Figure S4 Apoptotic index of the iPSC motor neuron
cultures. MN cultures from both SMA iPSC lines had
significantly more cells exhibiting characteristics of apoptotic
nuclei compared to both control iPSC MN cultures. n=3
experiments.
(TIF)
Figure S5 Motor neuron cultures are a mixed popula-
tion of neuronal, glial and non-neural cells. Glial and
neuronal cells are identified in motor neuron differentiating
cultures from SMA and CTR iPSCs by immunostaining for (A)
GFAP positive astrocytes and TuJ1 positive neurons, as well as (B)
ChAT stained cholinergic neurons can be identified in the
cultures. The cell population consists of ,25–40% non-neural
cells. Scale bars: 25 mm.
(TIF)
Table S1 Primer sets for RT-PCR and qRT-PCR. CDR (Tot.)
indicates primers that span the coding region of the gene allowing
for monitoring of total gene expression, whereas UTR (End.)
indicates primers that span the 39 or 59 untranslated region of the
gene allowing determination of endogenous gene expression.
(DOC)
Table S2 Antibodies used for immunocytochemistry, immuno-
blotting and apoptosis inhibition.
(DOC)
Text S1 Supporting materials and methods.
(DOC)
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